S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Generex Biotechnology Short Interest Ratio and Short Volume

+0.01 (+12.12%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
357,327 shs
Average Volume
448,016 shs
Market Capitalization
$11.29 million
P/E Ratio
Dividend Yield

Generex Biotechnology (OTCMKTS:GNBT) Short Interest Data

Current Short Volume
Previous Short Volume
Change Vs. Previous Month
Dollar Volume Sold Short
$6.36 thousand
Short Interest Ratio / Days to Cover
Last Record Date
November, 15 2021
Outstanding Shares
Percentage of Shares Shorted
Today's Trading Volume
Average Trading Volume
Today's Volume Vs. Average
Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Generex Biotechnology ?

Sign up to receive the latest short interest report for Generex Biotechnology and its competitors with MarketBeat's FREE newsletter.

Generex Biotechnology (OTCMKTS:GNBT) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
11/15/202160,600 shares $6.36 thousand +551.6%N/A0.1 $0.11
10/29/20219,300 shares $1.37 thousand -95.7%N/A0 $0.15
10/15/2021216,000 shares $35.99 thousand -3.0%N/A0.5 $0.17
9/30/2021222,700 shares $42.71 thousand +0.4%N/A0.5 $0.19
9/15/2021221,800 shares $39.88 thousand -3.9%N/A0.4 $0.18
8/31/2021230,900 shares $49.62 thousand +13.9%N/A0.5 $0.21
8/13/2021202,800 shares $41.57 thousand -1.6%N/A0.5 $0.21
7/30/2021206,000 shares $48.77 thousand -1.2%N/A0.5 $0.24
7/15/2021208,500 shares $49.25 thousand -5.1%N/A0.8 $0.24
6/30/2021219,600 shares $54.90 thousand -5.6%N/A0.4 $0.25
6/15/2021232,500 shares $55.29 thousand +8.9%N/A0.4 $0.24
5/28/2021213,500 shares $59.78 thousand -10.1%N/A0.6 $0.28
5/14/2021237,400 shares $65.33 thousand +13.9%N/A0.5 $0.28
4/30/2021208,500 shares $56.30 thousand -6.9%N/A0.5 $0.27
4/15/2021223,900 shares $58.77 thousand +4.9%N/A0.3 $0.26
3/31/2021213,500 shares $61.85 thousand -4.6%N/A0.4 $0.29
3/15/2021223,700 shares $85.01 thousand +1.7%N/A0.2 $0.38
2/26/2021219,900 shares $95.66 thousand -4.0%N/A0.2 $0.44
2/12/2021229,100 shares $98.54 thousand -36.0%N/A0.1 $0.43
1/29/2021358,200 shares $161.19 thousand -13.8%N/A0.2 $0.45
1/15/2021202,800 shares $62.20 thousand -36.7%N/A0.4 $0.31
12/31/2020204,600 shares $37.78 thousand +0.9%N/A0.2 $0.18
12/15/2020202,800 shares $44.01 thousand -36.7%N/A0.4 $0.22
11/30/2020320,600 shares $70.53 thousand +32.0%N/A0.2 $0.22
11/15/2020242,900 shares $48.31 thousand -44.9%N/A0.1 $0.20

Generex Biotechnology (OTCMKTS:GNBT) Short Interest Frequently Asked Questions

What is Generex Biotechnology's current short interest?

Short interest is the volume of Generex Biotechnology shares that have been sold short but have not yet been closed out or covered. As of November 15th, traders have sold 60,600 shares of GNBT short. Learn More on Generex Biotechnology's current short interest.

Is Generex Biotechnology's short interest increasing or decreasing?

Generex Biotechnology saw a increase in short interest in November. As of November 15th, there was short interest totaling 60,600 shares, an increase of 551.6% from the previous total of 9,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Generex Biotechnology's short interest compare to its competitors?

0.00% of Generex Biotechnology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Generex Biotechnology: Synthetic Biologics, Inc. (0.16%), CohBar, Inc. (0.00%), Cellectar Biosciences, Inc. (0.00%), Unicycive Therapeutics, Inc. (0.80%), Exicure, Inc. (3.04%), Yumanity Therapeutics, Inc. (2.33%), Addex Therapeutics Ltd (0.00%), Rockwell Medical, Inc. (3.59%), Forte Biosciences, Inc. (5.85%), and Acerus Pharmaceuticals Co. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.06 billion), S&P Global Inc. ($8.74 billion), Charter Communications, Inc. ($5.66 billion), Canadian Pacific Railway Limited ($5.43 billion), Wayfair Inc. ($4.23 billion), Palo Alto Networks, Inc. ($3.46 billion), DoorDash, Inc. ($3.41 billion), Teladoc Health, Inc. ($2.84 billion), Etsy, Inc. ($2.76 billion), and Zscaler, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Generex Biotechnology stock?

Short selling GNBT is an investing strategy that aims to generate trading profit from Generex Biotechnology as its price is falling. Generex Biotechnology's stock is trading up $0.01 today. To short Generex Biotechnology stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Generex Biotechnology will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Generex Biotechnology?

A short squeeze for Generex Biotechnology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GNBT, which in turn drives the price of the stock up even further.

How often is Generex Biotechnology's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNBT, twice per month. The most recent reporting period available is November, 15 2021.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.